Podbean logo
  • Discover
  • Podcast Features

    Your all-in-one podcasting solution.

    Podcast Studio

    Easy-to-use audio recorder app.

  • Livestream

    High-performing audio live, without limits.

  • Podcast App

    The best podcast player & podcast app.

  • Ads Marketplace

    Join Ads Marketplace to earn money
    through sponsorship on your podcast.

    PodAds

    Manage your ads with dynamic ad insertion capability.

  • Patron & Paid Content

    The seamless way for fans to support you directly
    from your podcast.

  • Apple Podcasts Subscriptions Integration

    Effortlessly publish and manage exclusive episodes for your
    Apple Podcasts subscribers directly from Podbean.

  • All Arts Business Comedy Education
  • Fiction Government Health & Fitness History Kids & Family
  • Leisure Music News Religion & Spirituality Science
  • Society & Culture Sports Technology True Crime TV & Film
  • Live
  • How to Start a Podcast
  • How to Start a Live Podcast
  • How to Monetize a podcast
  • How to Promote Your Podcast
  • How to Use Group Recording
  • Log in
  • Start your podcast for free
  • Podcasting
    • Podcast Features
    • Live Stream
    • PodAds
    • Podcast App
    • Podcast Studio
  • Monetization
    • Premium
    • Patron
    • Apple Podcasts Subscriptions Integration
    • Ads Marketplace
  • Enterprise
  • Pricing
  • Discover
  • Log in
    Sign up free
The NetworkNewsAudio Interviews Podcast

The NetworkNewsAudio Interviews Podcast

News:Business News

CNS Pharmaceuticals (NASDAQ: CNSP) Chairman and CEO, John Climaco Interview on Gamechangers LIVE

CNS Pharmaceuticals (NASDAQ: CNSP) Chairman and CEO, John Climaco Interview on Gamechangers LIVE

2020-12-09
Download

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, recently appeared on Gamechangers LIVE, a podcast series that shines a spotlight on gamechangers in various industries, sharing perspective on journeys, mindsets, struggles and successes in an effort to inspire and inform listeners. During the interview, CNSP’s chairman and CEO, John Climaco, provided an overview of CNS Pharmaceuticals and its lead drug candidate, Berubicin. Proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer, Berubicin was evaluated in a Phase I clinical trial. As a result of the trial, 44% of patients experienced a clinical benefit of stable disease or better, including one patient who experienced a durable complete response and remains cancer free 14 years after treatment. CNS recently submitted an Investigational New Drug (“IND”) application with the FDA, and, pending approval, it intends to commence a pivotal Phase II clinical trial in the U.S. “I have done all kinds of different things in my career, been in the health care industry for a long time. This is the most exciting thing that I’ve done,” Climaco said in the interview. “This company and our lead product have the potential to really change the landscape and the game in an area of oncology that hasn’t seen a lot of hope for a very long time in glioblastoma.”

To view the full press release, visit https://nnw.fm/jfjZB

CNS Pharmaceuticals (NASDAQ: CNSP) is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase 1 clinical trial with Berubicin in malignant brain tumors, which Reata conducted in 2006. In this trial the overall response rate of stable disease or better was 44%. This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders. One patient experienced a durable complete response and remains cancer-free as of February 20, 2020. These Phase 1 results represent a limited patient sample size and, while promising, are not a guarantee that similar results will be achieved in subsequent trials. Its second drug candidate, WP1244, is a novel DNA binding agent that has shown in preclinical studies that it is 500 times more potent than the chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation. 

view more

More Episodes

ev Transportation Services Inc. Interview [Video Edition]
2021-01-21
ev Transportation Services Inc. Interview
2021-01-21
Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) Interview [Video Edition]
2021-01-13
Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) Interview
2021-01-13
InvestorBrandNetwork Announces Want Money Got Money Podcast with CNS Pharmaceuticals Inc. Chairman and CEO John Climaco
2020-12-16
InvestorBrandNetwork Announces Want Money Got Money Podcast with CNS Pharmaceuticals Inc. Chairman and CEO John Climaco [Video Edition]
2020-12-16
CNS Pharmaceuticals (NASDAQ: CNSP) Chairman and CEO, John Climaco Interview on Gamechangers LIVE [Video Edition]
2020-12-09
Gage Cannabis Co. Interview [Video Edition]
2020-12-08
Pac Roots Cannabis Corp. (CSE: PACR) Interview [Video Edition]
2020-12-08
Gage Cannabis Co. Interview
2020-12-08
Pac Roots Cannabis Corp. (CSE: PACR) Interview
2020-12-08
GoldHaven Resources Corp. (CSE: GOH) (OTCQB: ATUMF) Interview [Video Edition]
2020-12-02
GoldHaven Resources Corp. (CSE: GOH) (OTCQB: ATUMF) Interview
2020-12-02
Predictive Oncology (NASDAQ: POAI) Interview [Video Edition]
2020-10-27
Predictive Oncology (NASDAQ: POAI) Interview
2020-10-27
The Alkaline Water Company Inc. (CSE: WTER) (NASDAQ: WTER) Interview [Video Edition]
2020-10-06
The Alkaline Water Company Inc. (CSE: WTER) (NASDAQ: WTER) Interview
2020-10-06
Cybin Corp. Interview [Video Edition]
2020-09-15
Cybin Corp. Interview
2020-09-15
  • ←
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • →
01234578910111213141516171819

Get this podcast on your
phone, FREE

Download Podbean app on App Store Download Podbean app on Google Play

Create your
podcast in
minutes

  • Full-featured podcast site
  • Unlimited storage and bandwidth
  • Comprehensive podcast stats
  • Distribute to Apple Podcasts, Spotify, and more
  • Make money with your podcast
Get started

It is Free

  • Podcast Services

    • Podcast Features
    • Pricing
    • Enterprise Solution
    • Private Podcast
    • The Podcast App
    • Live Stream
    • Audio Recorder
    • Remote Recording
  •  
    • Create a Podcast
    • Video Podcast
    • Start Podcasting
    • Start Radio Talk Show
    • Education Podcast
    • Church Podcast
    • Nonprofit Podcast
    • Get Sermons Online
    • Free Audiobooks
  • MONETIZATION & MORE

    • Podcast Advertising
    • Dynamic Ads Insertion
    • Patron Program
    • Apple Podcasts Subscriptions
    • Switch to Podbean
    • Submit Your Podcast
    • Podbean Plugins
    • Developers
  • KNOWLEDGE BASE

    • How to Start a Podcast
    • How to Start a Live Podcast
    • How to Monetize a podcast
    • How to Promote Your Podcast
    • How to Use Group Recording
  • Support

    • Support Center
    • What’s New
    • Free Webinars
    • Podcast Events
    • Podbean Academy
    • Podcasting Smarter
    • Badges
    • Resources
  • Podbean

    • About Us
    • Podbean Blog
    • Careers
    • Press and Media
    • Green Initiative
    • Affiliate Program
    • Contact Us
  • Privacy Policy
  • Cookie Policy
  • Terms of Use
  • Consent Preferences
  • Copyright © 2015-2023 Podbean.com